162P - Molecular markers in advanced non small cell lung cancer patients receiving gemcitabine & cisplatin

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Anticancer agents
Translational Research
Non-Small Cell Lung Cancer
Basic Principles in the Management and Treatment (of cancer)
Biological Therapy
Presenter Maha Ismail
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors M. Ismail1, A. Abdelgawad1, R. Gaafar1, A. Bahnassy2, N. Allahloubi1
  • 1Medical Oncology, National Cancer Institute, 11796 - Cairo/EG
  • 2Molecular Pathology, National Cancer Institute, 11796 - Cairo/EG



Despite improvement in the standard treatment of advanced Non Small Cell Lung Cancer (NSCLC), the overall prognosis is very poor. Using molecular markers as a predictor for chemotherapy response is a hot area of research.


This is a prospective study conducted in National Cancer Institute (NCI), Cairo University, including eligible patients with advanced NSCLC who received first line chemotherapy (Gemcitabine and Cisplatin). ERCC1, BRCA1 and RRM1proteins level in blood samples by ELISA and their genes expression by PCR were detected. The primary objective was the correlation between molecular markers and clinical response (CR), while the secondary objectives were assessment of correlation between expression of these markers and Time To Progression (TTP) and Overall Survival (OS).


71 patients included and followed up during the period from Jan 2011 to Jan 2014 with median follow up 5.6 months. There was no significant correlation between ERCC1, RRM1 and BRCA1expression and clinical response (p values = 0.14, 0.65, 0.67 respectively). Patients with high ERCC1 expression had shorter TTP (3.5 vs 6.1 months; P = 0.001) and OS (6.6 vs 10.9 months; P = 0.022), Patients with low RRM1 expression had almost the same TTP of patients with high RRM1 (4.2 vs 4.7 months; p value = 0.91); but they had longer OS (10.8 vs 7.0 months; P = 0.052). No significant correlation between the BRCA1 expression and survival were found (TTP was 4.8 months in patients with high expression versus 4.7 months in low expression; P value = 0.7) (OS was 10.5 months in patients with high expression versus 7.8 months in low expression; P value = 0.46).


High expression of ERCC1 and RRM1 are associated with poor outcome in patients with advanced NSCLC treated with Gemcitabine and Cisplatin, ERCC1 and RRM1may considered as predictive and prognostic markers for patients receiving Gemcitabine and Cisplatin.

Clinical trial identification

Legal entity responsible for the study

National Cancer Institute


National Cancer Institute, Cairo, Egypt


All authors have declared no conflicts of interest.